The Pulmonary-Critical Care Medicine Branch of the National Heart, Lung, and Blood
Institute (NHLBI) at the National Institute of Health (NIH) in Bethesda, Maryland has
initiated a drug study of individuals with sarcoidosis.
The protocol is a great opportunity for patients with pulmonary sarcoidosis to contribute
to research and to benefit from the testing and evaluation by expert physicians at
the NHLBI. This is a randomized double blind study in which patients with pulmonary
sarcoidosis will receive pentoxyfylline or a placebo for nine months.
The protocol includes an initial three to five day admission for inpatient studies involving a
medical evaluation, chest x-ray, EKG, fiberoptic bronchoscopy, as well as other
routine pulmonary testing. Any part(s) of testing may be declined by the patient. The patient will be
asked to return for repeat studies for six additional visits. There will be no charge for this evaluation. In
addition, transportation expenses will be paid.
Any patient with sarcoidosis who participates in this study will continue to remain under
the care of their own physician. A summary of the evaluation findings will be sent to the
referring physician. If you are interested in an evaluation and possible enrollment in this
protocol, the following information is requested.
Referral letter - medical history including, medications and surgeries
Copy of most recent Pulmonary Function Test, if available
Biopsy slides with pathology report and, if available, paraffin tissue blocks
Please send all information to:
Dr. Joel Moss
Pulmonary-Critical Care Medicine Branch
National Institute of Health, Bldg. 10, Room 6D03
10 Center Drive, MSC 1590
Bethesda, MD 20892-1590
If you have any additional questions or seek further information, please contact the clinical
research nurses,
Pauline Barnes, RN or Ruth Litzenberger, RN at 1-877-644-5864 (toll free)